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Background
PAPA syndrome (pyogenic sterile arthritis, pyoderma
gangrenosum and acne) is a rare autosomal-dominant
autoinflammatory disease caused by mutations in
PSTPIP1gene. Typically presents with recurrent sterile,
erosive arthritis in childhood, occurring spontaneously or
after minor trauma, occasionally resulting in significant
joint destruction. By puberty, joint symptoms tend to sub-
side and cutaneous symptoms increase. Cutaneous mani-
festations include pathergy, frequently with abscesses at
the sites of injections, severe cystic acne, and recurrent
nonhealing sterile ulcers, often diagnosed as PG.
Objective
To report a case of hepatitis B infection revealed with
interleukin-1 receptor antagonist for PAPA syndrome.
Patient and method
16,5y boy with PAPA syndrome presenting at age 2 with
pyogenic sterile arthritis requiring multiple surgeries
(shoulders, elbows, knees, ankles, wrists). He was treated
as JIA for 14y (NSAID, steroids (11 years, had growth
retardation due to steroids), immunosupressants (meto-
trexate) and for short time biologicals (infliximab, adali-
mumab). Several years ago developed severe acne and
nonhealing skin ulcers. In august 2013, the boy was
referred to our Department and completely reevaluated.
He had raised inflammatory markers, microcytic anaemia,
normal transaminases. Skin biopsy: pyoderma gangreno-
sum. Kidney biopsy excluded amyloidosis. Started with
adalimumab for 1 year. Joint disease was under control,
but not skin disease. Clinical diagnosis of PAPA syndrome
was confimed by genetic analysis in March 2014. He was
heterozygous for the substitution 748G>C in exon 11 that
predicts the E250Q aminoacid substitution. When avail-
able, adalimumab was switched to anakinra in November
2014 (after washout period of 8 weeks). One month later,
the patient showed raised transaminases (10 times above
upper limit of normal). Active hepatitis B infection was
proved by PCR. His mother had hepatitis B and boy had
several surgeries with blood transfusions. How did he har-
bour the infection? Anakinra was stopped. On sympto-
matic therapy, transaminasemia soon normalised, but
PAPA worsened. At present, he is on antiviral therapy and
the issue if and when anakinra should be restarted.
Conclusion
We reported a boy with genetically confirmed PAPA
syndrome. Treatment with adalimumab controlled joint
but not skin disease. Interleukin-1 receptor antagonist
was associated with activation of previously unknown
hepatitis B infection, requiring antiviral therapy and
withdrawal of treatment with anakinra. This case raises
the question of the possible role of anakinra in activat-
ing the viral infection and the usefullness routine srce-
ening for hepatitis B prior biological.
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